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Abstract  Liver  diseases  are  a  major  health  problem  worldwide,  making  it  necessary  to  develop
new molecules  that  help  counteract  or  prevent  such  diseases.  On  account  of  this  fact,  inves-
tigations aiming  to  obtain  natural  and/or  synthetic  compounds  possessing  hepatoprotective
activity have  been  undertaken.  The  development  of  new  drugs  consists  of  a  variety  of  steps,
ranging from  the  discovery  of  the  pharmacological  effects  in  cellular  and  animal  models,  to
ﬁnally demonstrate  their  efﬁcacy  and  safety  in  humans.  Different  models  for  assessment  of
the hepatoprotective  activity  in  vitro,  ex  vivo  and  in  vivo  can  be  found  in  medical  literature.
The purpose  of  this  review  is  to  show  the  features,  main  advantages  and  disadvantages  of  each
of the  models,  the  hepatotoxic  agents  most  commonly  used  (CCl4,  acetaminophen,  ethanol,  d-
galactosamine,  t-BuOOH,  thioacetamide)  as  well  as  the  biochemical  parameters  useful  to  assess
liver damage  in  the  different  models.
© 2016  Universidad  Auto´noma  de  Nuevo  Leo´n.  Published  by  Masson  Doyma  Me´xico  S.A.  This  is
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he  liver  is  a  key  organ.  It  regulates  different  functions
n  the  body,  such  as  metabolism,  secretion,  storage  and
etoxifying.  Liver  damage  is  usually  associated  with  the  dis-
ortion  of  some  of  these  functions.  The  liver  is  continuously
xposed  to  an  elevated  amount  of  toxic  agents,  because
he  portal  vein  supplies  blood  to  this  organ  after  intestinal
bsorption.1,2
The  World  Health  Organization  (WHO)  determined  that
round  2.4  million  deaths  yearly  are  linked  to  some  liver
isease,  and  that  around  800  thousand  of  these  deaths  are
ttributable  to  cirrhosis.3 On  the  other  hand,  epidemiologi-
al  studies  conducted  by  the  National  Institute  of  Statistics
asson Doyma Me´xico S.A. This is an open access article under the
.0/).
Hepatoprotective  activity  assessment  
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independently  in  the  organism;  on  the  contrary,  they  formFigure  1  Mechanism  of  liver  damage  due  to  oxidative  stress.
and  Geography  (INEGI  by  its  Spanish  acronym)  indicate
that  in  2013  in  Mexico,  over  600  thousand  deaths  were
recorded.  The  main  causes  were  diabetes  mellitus  (14.25%),
followed  by  ischemic  heart  diseases  (12.63%),  cerebrovascu-
lar  diseases  (5.29%)  and  liver  diseases  (4.79%).  Despite  the
advances  in  modern  medicine  and  the  development  of  new
hepatoprotective  drugs,4--6 the  incidence  of  hepatic  diseases
has  not  decreased  or  stopped;  on  the  contrary,  statistics
suggest  that  these  continue  to  increase.7,8
Metabolism  or  biotransformation  of  hepatotoxic  agents
is  a  detoxifying  process  where  molecules  are  surgically
modiﬁed  into  less  toxic  shapes  by  different  enzymatic  sys-
tems.  These  modiﬁcations  can  generate  metabolic  products
with  varying  degrees  of  pharmacological  activity  or  inactive
metabolites.  There  are  different  types  of  metabolic  reac-
tions:  phase  1  reactions  are  usually  oxidations,  reductions  or
hydrolysis  (modifying  the  structure  of  the  reactive  group);
phase  2  reactions  are  those  in  which  the  drug  conjugates
with  glucuronic  acid,  sulfates,  acetates,  methyl  groups,  glu-
tathione  or  amino  acids,  generally  to  increase  its  solubility
and  be  excreted.  The  liver’s  ability  to  be  able  to  carry  out
the  different  oxidative  metabolisms  is  associated  with  the
high  cytochrome  P450  cell  content.9
Due  to  the  high  metabolite  biotransformation  rate,  free
radicals  can  be  generated  continuously.  Most  hepatotoxic
substances,  mainly  damage  the  liver  because  of  the  gen-
erated  oxidative  stress;  oxygen  reactive  species  induced  a
rise  in  lipid  peroxidation,  a  reduction  of  ATP  and  oxidative
damage  in  the  DNA  and  proteins  (Fig.  1).10--13
Protecting  the  liver  from  the  harmful  effects  of
hepatotoxins-  which  may  be  ingested-  or  counteracting  the
alterations  in  the  antirradical  defense  mechanisms,  is  very
important;  the  agents  capable  of  doing  this  are  called
hepatoprotective.14
For  this  reason,  researches  have  been  developed
in  the  search  of  natural  and/or  synthetic  compounds
with  hepatoprotective  activity.8 The  development  of  new
pharmaceuticals  consists  of  a  variety  of  steps,  going  from
the  discovery  of  pharmacological  side  effects  in  cellular  and
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nimal  models,  to  ﬁnally  prove  its  efﬁcacy  and  safety  in
uman  beings.1
In  vivo  and  well  as  ex  vivo  test  models  are  used  to
valuate  hepatoprotective  activity.  These  systems  mea-
ure  the  ability  of  the  drug  to  prevent  or  cure  hepatic
oxicity  (induced  by  different  hepatotoxins)  in  cellular  cul-
ures,  organs  or  in  experimental  animals  (rats,  mice,  etc.)
espectively.1
valuation models
early  every  acute  and  chronic  liver  injury  can  be  exper-
mentally  induced;  necrosis,  steatosis,  hepatic  injuries,
irrhosis  and  cholestasis.  These  can  all  be  generated  in  dif-
erent  models  of  liver  damage.
The  objective  of  hepatoprotective  models  is  for  the  com-
ounds,  fractions  or  extracts  being  tested  to  counteract
r  avoid  the  damage  generated  by  hepatotoxins.  The  mag-
itude  of  the  hepatoprotective  effect  can  be  measured
hrough  biochemical  makers,  survival  rate  or  histology  of
he  liver.
Test  methods  may  be  in  vitro,  ex  vivo  or  in  vivo  (Table  1);
nd  each  one  of  them  can  be  evaluated  to  see  if  the  sub-
tance  is  hepatoprotective  or  hepatocurative,  depending  on
f  the  hepatoprotective  agent  is  administered  before  or  after
he  hepatotoxin.
n  vitro  models
resh  hepatocytes,  primary  hepatocyte  cultures  and  immor-
alized  cell  lines  are  used  to  measure  the  hepatoprotective
ffect.  It  is  possible  to  establish  action  mechanisms  in  these
odels.  These  models  represent  the  best  option  for  the
creening  and  selection  of  potential  hepatoprotective  com-
ounds  and  it  is  possible  to  establish  action  mechanisms  at
 cellular  and  molecular  level.15,16
Primary  hepatocyte  cultures  have  the  characteristic  of
aintaining  normal  metabolic  liver  properties,  but  it  is  not
ossible  to  maintain  them  for  a  long  time.  On  the  other  hand,
ell  lines  maintain  their  properties  stable  for  a  long  time
nd  can  be  cryopreserved,  but  immortalized  or  carcinogenic
ines  may  differ  in  biochemical  and  metabolic  aspects  from
ormal  cells.1
In  order  to  evaluate  protection,  parameters  like
ransaminase  liberation,  cell  multiplication,  morphology,
acromolecular  synthesis,  oxygen  consumption,  etc., are
easured.17,18
Advantages  of  in  vitro  models  are:  They  are  quick  tests
between  2--3  testing  days),  they  require  small  amounts  of
he  test  substances  (milligram  range)  and  the  experimen-
al  conditions  may  be  strictly  controlled;  different  samples
ay  be  analyzed  in  the  same  test,  they  are  cheap  tests  and
here  is  little  variability;  therefore  they  are  considered  a
eproducible  test.  In  the  case  of  primary  cultures  or  fresh
epatocytes,  they  require  few  experimental  animals  in  com-
arison  to  in  vivo  models.
Disadvantages  of  in  vitro  models:  cells  do  not  functionlose  and  complicated  nets  with  each  other  and  with  the
xtracellular  matrix;  therefore,  this  should  be  taken  into
onsideration  when  interpreting  in  vitro  data  and  should
224  C.  Delgado-Montemayor  et  al.
Table  1  Models  of  evaluations  of  hepatoprotective  activity.
Model  Examples  Advantages  Disadvatages
In  vitro  *  Fresh  hepatocytes
* Primary  hepatocyte
culture
*  Immortalized  cell  lines
(HepG2,  HUH7,  HepRG)
*  Quick  and  cheap  tests
* Requires  few  samples
*  High  control  of
variables;  reproducible
* Can  analyses  various
samples  in  the  same  test
*  Due  to  a  lack  of  complexity  present
in the  organ  of  biological  system,
results  should  be  interpreted  with
caution.
* Samples  do  not  undergo  any
biotransformation  process
Ex vivo  *  Precise  liver  cuts
* Isolated  perfused  liver
*  Resemble  the  in  vivo
environment
* Decrease  the  number
of  animals  experimented
on
*  A  human  tissue  model
can  be  developed
*  Low  oxygenation  rate  in  the
internal  cells
*  Low  cut  viability  (1--10  días)
* There  are  signiﬁcant  differences  in
size and  fuction  between  human  and
murine  tissue.
In vivo  *  Murine  model  *  Widely  used
*  There  is  a  greater
correlation  with  what
happens  in  humans
* All  biochemical  and
histological  parameters
can  be  measured
*  Requires  a  large  number  of  animals
to experiment  on
*  Interindividual  variation  exists
* A  larger  simple  size  is  required
* Large  and  expensive  experiments
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he  veriﬁed  with  in  vivo  systems.  Isolated  cells  as  well  as
ell  lines  have  an  elevated  cell  differentiation  rate  due  to
he  loss  of  natural  environment.  The  substances  tested  do
ot  go  through  the  absorption  and  distribution  processes,
hich  occurs  in  the  organism.  There  is  little  to  no  cell-to-
ell  interaction  and  there  is  no  complexity  proper  of  the
rgan.19--21
x  vivo  models
recision  cut  liver  slices  (PCLS)  are  an  ex  vivo  tissue  culture
hich  imitates  multicellular  characteristics  of  in  vivo
rgans.  Cellular  interaction  and  spatial  disposition  remain
ntact  in  this  model,  with  the  possibility  of  performing  mor-
hological  studies.  Liver  slices  have  the  characteristic  of
unctionally  maintaining  metabolizing  enzymes  and  biliary
analiculus21;  they  have  proven  to  be  a  valid  ex  vivo  sys-
em  to  study  metabolism  and  liver  damage  and  function  as
 bridge  between  in  vivo  systems  and  cell  cultures.22
Isolated  perfused  livers  represent  a  model  combining
n  vitro  characteristics  under  in  vivo  circumstances.  The
rst  model  was  developed  in  porcine  livers  and  later  the  liv-
rs  of  smaller  animals  (rats,  mice  and  rabbits).  This  model
reserves  the  tridimensional  structure  as  well  as  the  cell-to-
ell  interactions  with  the  possibility  of  collecting  bile  in  real
ime.  If  blood  is  used  as  a  perfusor  liquid,  then  hemodynamic
arameters  may  be  studied.23
Advantages  of  ex  vivo  models:  they  resemble  in  vivo
tmospheres,  are  low  cost,  reproducible  models.  In  PCLS  the
umber  of  experimental  animals  is  reduced,  also  the  model
an  be  developed  with  human  organs.
Disadvantages  of  ex  vivo  models:  in  PCLS  the  bile  ﬂow
nd  functional  parameters,  such  as  portal  ﬂow,  cannot  be
nalyzed.1 There  is  poor  diffusion  of  oxygen  nutrients  to
t
s
e
ahe  more  internal  cells,  and  even  with  the  development  of
ew  means  of  culture,  the  viability  of  the  slices  remains
hort  (8--10  Days).22 In  small  labs,  because  of  space  and
udget,  the  best  option  is  the  development  of  perfused  rat
iver;  however,  there  are  signiﬁcant  differences  in  the  size,
unction  and  geometry  of  the  murine  liver  compared  to  the
uman.1
n  vivo  model
his  model  has  been  widely  used;  through  this  model  we
re  able  to  determine  the  protection  mechanism.  The  dam-
ge  produced  in  experimental  animals  due  to  known  dosage
dministration  of  different  hepatotoxins  and  the  magni-
ude  of  the  damage  and/or  protection  is  determined  by
he  different  biochemical  and  metabolic  markers,  as  well
s  histopathological  determinations.
Advantages  of  in  vivo  models:  is  the  model  with  the  high-
st  degree  of  correlation  with  what  occurs  in  humans  and  all
iochemical  and  histopathological  parameters  can  be  mea-
ured.  They  let  us  take  into  account  the  possible  effects  of
he  immune  and  central  nervous  systems  in  the  development
f  hepatic  diseases.24
Disadvantages  of  in  vivo  models:  they  require  a  large
umber  of  animals,  and  usually  the  studies  are  developed
or  long  periods  of  time,  increasing  ethical  and  ﬁnancial
spects.  There  is  an  inter-individual  variation,  and  even
hough  models  imitating  the  different  hepatic  diseases
ave  been  developed,  there  are  relevant  differences  in
he  molecular  pathogenesis  between  the  model  and  human
pecies.  They  require  a  larger  sample  size  to  perform  the
xperiment  which  may  be  a  limiting  factor,  especially  when
nalyzing  natural  products.25
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(Hepatoprotective  activity  assessment  
Hepatotoxic agents and their action
mechanisms
The  molecules  responsible  for  liver  damage  are  called  hep-
atotoxins;  nowadays  it  is  possible  to  imitate  any  form  of
natural-origin  hepatic  disease  with  different  chemical  sub-
stances  and  pharmaceuticals.
Hepatotoxins  may  be  classiﬁed  as  intrinsic  if  the  agent’s
behavior  is  predictable;  there  is  a  period  of  constant
latency  between  exposure  and  liver  damage  development,
or  the  injury  is  dose-dependent  (i.e.  carbon  tetrachloride
{CCl4},  thioacetamide,  acetaminophen,  ethanol).  Another
classiﬁcation  is  idiosyncratic,  if  the  agents  are  not  pre-
dictable,  but  generate  liver  damage  in  just  a  small  portion
of  exposed  individuals,  the  injury  is  not  related  to  the
dosage,  it  occurs  after  a  variable  latent  period  and  it  is
not  reproducible  in  experimental  animals  (i.e.  halothane,
sulfonamides,  isoniazid).26,27
Carbon  tetrachloride  (CCl4)
CCl4 toxicity  depends  on  dosage  and  the  duration  of  expo-
sure.  In  low  dose,  effects  like  loss  of  Ca2+ homeostasis,  lipid
peroxidation,  and  release  of  cytokines  are  produced,  and
apoptotic  events  may  be  generated,  followed  by  cellular
regeneration.  In  high  doses,  or  if  there  is  a  longer  exposure,
the  effects  are  more  severe  and  the  damage  occurs  during
a  longer  period  of  time,  the  patient  may  develop  ﬁbrosis,
cirrhosis,  or  even  cancer.5,28,29
CCl4 is  metabolized  by  the  cytochrome  P450  dependent  of
monooxygenases,  mainly  through  the  CYP2E1  isoform  in  the
endoplasmic  reticulum  and  mitochondria.16 Hepatotoxicity
is  produced  by  the  formation  of  the  trichloromethyl  radical
(CCl3),  which  is  highly  reactive.  These  radicals  may  satu-
rate  the  organism’s  antioxidant  defense  system,  react  with
proteins,  attack  unsaturated  fatty  acids,  generating  lipid
peroxidation,  reduce  the  amount  of  cytochrome  P450,  which
leads  to  a  functional  failure  with  the  consequent  lowering  of
protein  and  accumulation  of  triglycerides  (fatty  liver),  and
alter  water  and  electrolyte  equilibrium  with  an  increase  of
hepatic  enzymes  in  plasma.30
Lipid  peroxidation  leads  to  a  cascade  of  reactions,  such
as  the  destruction  of  membrane  lipids,  the  generation  of
endogenous  toxic  substances,  which  originate  more  hepatic
complications  and  functional  anomalies.  For  this  reason,
lipid  peroxidation  is  considered  a  critical  factor  in  the  patho-
genesis  of  liver  injuries  induced  by  CCl4.15 The  inhibition  of
the  radical  CCl3 generation  is  a  key  point  in  the  protec-
tion  against  the  damage  generated.  Because  of  this,  this
model  is  widely  used  for  the  evaluation  of  pharmaceuticals
and  natural  products  with  hepatoprotective  and  antioxidant
activity.31,32
AcetaminophenIt  is  an  analgesic  antipyretic  analgesic.  In  high  doses,  it
produces  acute  liver  damage,  causing  necrosis  of  the  hepa-
tocytes.  It  is  a  widely  used  experimental  model  of  clinical
importance  as  an  example  of  drug-induced  liver  damage.16
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At  therapeutic  doses,  it  is  mainly  metabolized  to  glu-
uronic  or  sulfated  and  excreted  derivatives,  the  rest
etabolizes  to  intermediate  reactives,  which  are  elimi-
ated  by  conjugation  with  glutathione.  At  overdoses,  the
xcess  is  oxidized  by  the  cytochrome  P450  (mainly  the
YP2E1  isoform)33 at  N-acetyl-p-benzoquinone  (NAPQI),
hich  quickly  attaches  to  glutathione.  Under  excessive  con-
itions  of  NAPQI  and  glutathione  depletion,  a  covalent  bond
f  metabolite  to  proteins,  adduct  formation,  mitochondrial
ysfunction  and  oxidative  stress  occurs.  The  result  is  necro-
is  or  hepatocellular  death.19,34
thanol
he  liver  is  the  most  susceptible  organ  to  the  toxic  effects  of
thanol.  The  damage  mechanism  is  due  to  the  metabolism
f  ethanol  by  the  CYP2E1  isoform  of  the  cytochrome
450  producing  oxidative  stress  with  the  generation  of
eactive  species  of  oxygen  and  the  increase  of  lipid  per-
xidation,  leading  to  the  alteration  of  the  compositions
f  phospholipids  of  the  cellular  membrane.35,36 Membrane
ipid  peroxidation  results  in  the  loss  of  its  structure  and
ntegrity,  elevating  serum  levels  of  glutamyl-transpeptidase,
 membrane-bonding  enzyme.  Ethanol  inhibits  glutathione
eroxidase;  it  reduces  the  activity  of  catalase  and  dismutase
uperoxide.16
The  decrease  in  the  activity  of  antioxidant  enzymes,  dis-
utase  superoxide  and  peroxidase  glutathione  is  believed  to
ome  as  a  result  of  the  harmful  effects  of  free  radicals  pro-
uced  after  exposure  to  ethanol,  or  alternatively,  they  could
e  a  direct  effect  of  acetaldehyde,  a  product  of  ethanol
xidation.
-Galactosamine
his  hepatotoxin  generates  a  similar  damage  to  viral  hepati-
is  regarding  morphologic  and  functional  characteristics.  A
ingle  dose  can  cause  hepatocellular  necrosis  and  fatty  liver.
It  induces  the  exhaustion  of  the  uracil  nucleotide,  result-
ng  in  the  inhibition  of  RNA  synthesis  and  consequently
f  proteins.37 The  toxicity  mechanism  causes  loss  of  the
ctivity  of  ion  pumps  and  an  increase  in  cellular  mem-
rane  permeability,  leading  to  enzyme  liberation  and  an
ncrease  in  intracellular  Ca2+ concentration,  which  is  con-
idered  responsible  for  cellular  death.16,36,38
ert-Butyl  hydroperoxide  (t-BuOOH)
etabolized  to  free  radicals  by  cytochrome  P450  in
epatocytes  generating  lipid  peroxidation,  a  decrease  of
lutathione,  it  reduces  the  potential  of  the  mitochondrial
embrane  and  cellular  damage;  generated  damage  is  simi-
ar  to  oxidative  stress,  which  occurs  in  cells  and  tissues.36,39
Alternatively,  t-BuOOH  can  be  converted  by  glutathione
eroxidase  into  tetr-butyl  alcohol  and  glutathione  disulﬁde
GSSG).  GSSG  is  converted  into  reduced  glutathione  (GSH)
y  the  GSSG  reductase,  generating  the  oxidation  of  pyridine
ucleotides  (NAPD).  All  these  events  alter  the  homeostasis
f  Ca+2 which  is  considered  a  critical  event  to  provide  open-
ngs  in  the  plasmatic  membrane,  and  thus  cellular  damage.40
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hioacetamide
n  organic  compound  containing  sulfur,  originally  used  as  a
ungicide  and  currently  used  for  the  treatment  of  leather,  in
abs  and  in  the  textile  and  paper  industries.29 It  can  induce
cute  and  chronic  hepatic  injuries  and  acts  over  the  synthe-
is  of  protein,  DNA,  RNA  and  over  -glutamyl  transpeptidase
GGT)  activity.
Thioacetamide  is  bio-activated  by  the  CYP450  and/or  by
he  monooxigenase  system,  which  contains  ﬂavin,  convert-
ng  the  compound  into  sulﬁne  (a  sulfoxide-type  compound)
nd  later  into  sulfone-type  compounds.  Sulﬁne  is  responsible
or  generating  an  increase  in  the  nucleus  volume,  nucle-
li  enlargement,  an  increase  in  intracellular  concentration
f  Ca+2,  generating  changes  in  cellular  permeability  and
itochondrial  dysfunction.  On  the  other  hand,  Sulfone-type
ompounds  are  responsible  for  the  liberation  of  nitric  oxide
ynthase  and  the  nuclear  factor  kappa  B  (NF-B), protein
enaturalization  and  lipid  peroxidation.41--43
iver function markers
 decisive  step  when  biological  activity  models  are  per-
ormed  is  the  analysis  of  the  activity  of  the  tested  analyte.
epending  on  the  selected  model  and  its  characteristics,
he  survival  rate  and  the  damaged  biochemical  markers  can
e  determined.  Due  to  the  wide  variety  of  functions  per-
ormed  by  the  liver,  there  is  a  wide  range  of  markers  through
hich  we  are  able  to  determine  the  functionality  or  damage
enerated  by  this  organ  or  its  cells.28 Although  there  is  no
iochemical  marker  speciﬁc  to  liver  damage,  the  combina-
ion  of  several  of  these,  and  knowing  the  correlation  they
ave  with  the  liver,  will  help  to  better  interpret  the  results
f  the  hepatoprotective  models.  Markers  can  be  divided  into
ests  related  to  the  liver’s  excretory  function  (bilirubin),
ests  related  to  synthetic  function  (albumin  and  prothrom-
in  time)  and  tests  related  to  the  integrity  of  hepatocytes
transaminases,  alkaline  phosphatase,  GGT).
ransaminases  or  aminotransferases
ransaminases  or  aminotransferases  are  enzymes  that  trans-
er  a  group  of  amino  from  an  amino  acid  to  an  acid
-acetate.  This  process  is  an  important  step  in  the
etabolism  of  amino  acids.  The  aspartate  aminotrans-
erase  (AST)  and  the  alanine  aminotransferase  (ALT)  are
idely  used  enzymes;  the  increase  in  the  liberation  of
hese  transaminases  is  linked  to  liver  dysfunction.  ALT  cat-
lyzes  the  amino  group  transference  of  the  L-alanine  to
-ketoglutarate  to  produce  pyruvate  and  L-glutamate;  it  is
levated  in  hepatic  and  renal  diseases,  i.e.  hepatitis,  cir-
hosis  and  mononucleosis.  AST  catalyzes  the  transference
f  the  amino  group  of  the  L-aspartate  to  -ketoglutarate  to
roduce  oxaloacetate  and  L-glutamate;  the  heart,  liver  and
keletal  muscle,  are  organs  rich  with  this  enzyme  and  the
ST  liberation  is  proportional  to  the  damage  generated.  In  a
yocardial  infarction  it  starts  to  increase  between  3  and  9  h
fter  the  event,  reaching  its  peak  on  the  second  day;  the
evels  normalize  between  the  fourth  and  the  sixth  day.  In
epatitis  cases,  observed  elevations  are  between  7  and  12
h
p
cC.  Delgado-Montemayor  et  al.
imes  its  normal  concentrations,  with  increases  of  up  to  100
imes.28
hosphatases
hese  enzymes  belong  to  the  hydrolases  family  and  are
nown  for  their  ability  to  hydrolyze  a wide  variety  of
rganophosphate  compounds  with  the  formation  of  phos-
hate  ions  and  alcohols.  Clinically  relevant  phosphatases  are
cid  phosphatase  and  alkaline  phosphatase.  Alkaline  phos-
hatase  (ALP)  is  produced  mainly  in  the  liver  and  bone;  when
here  are  no  osteogenic  diseases,  ALP  elevation  is  gener-
lly  linked  to  hepatobiliary  diseases.  It  is  more  speciﬁc  in
bstructive  hepatic  processes.28,44
ranspeptidase  -glutamine  (GGT)
his  enzyme  is  bound  to  the  plasmatic  membrane,  which
atalyzes  the  transference  of  the  -glutamine  group  of  a
eptide  to  itself  or  other  peptides.  It  is  located  mainly  in
epatocytes;  however  it  can  also  be  found  in  the  proximal
enal  tubules,  intestinal  epithelial  cells  and  the  prostate.
igh  GGTP  levels  usually  indicate  infection  in  the  liver,
ancreatic  and  biliary  zones.  The  speciﬁcity  of  the  test  is
elatively  low,  but  since  it  is  not  linked  to  bone  diseases,  it
s  used  to  link  high  ALP  levels  to  liver  damage.44
ilirubin
ilirubin  is  the  most  important  metabolite  of  the  heme
roup,  found  in  hemoglobin,  myoglobin  and  cytochromes.
t  is  highly  insoluble  in  water  in  its  most  common  isomeric
orm,  and  most  of  it  is  transported  by  albumin.  The  liver
s  responsible  for  eliminating  bilirubin  by  turning  it  to  a
ore  hydrosolube  compound,  thus  allowing  its  elimination
f  plasma  for  its  eventual  excretion.  It  is  the  most  important
est  of  the  hepatic  metabolic  function;  however,  it  is  only
ossible  to  determine  it  in  in  vivo  models.44
otal  proteins
he  liver  synthetizes  most  plasmatic  proteins,  and  in  most
epatic  diseases  the  levels  are  reduced.  Albumin,  -1  antit-
ypsin,  ceruloplasmin,  and  -fetoprotein  are  proteins  linked
o  acute  liver  damage.
actato  deshydrogenase  (LDH)
actato  deshydrogenase  is  an  enzyme  located  in  the  cellular
ytoplasm.  It  catalyzes  the  interconversion  of  the  lactate
nd  pyruvate;  LDH  liberation  may  be  interpreted  as  the
pening  of  the  cellular  membrane  or  cellular  death.  This
nzyme  is  not  speciﬁc  to  the  liver  and  it  is  widely  used
n  in  vitro  models  because  it  is  expressed  in  most  cellular
ines.45AST,  ALT  and  ALP  are  most  commonly  analyzed  in  all
epatoprotective  models,  while  the  quantiﬁcation  of  total
roteins  and  LDH  are  generally  used  as  parameters  of  in  vitro
ytotoxicity.46
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Conclusions
Liver  diseases  are  a  major  health  problem,  domestically
and  around  the  world;  thus,  it  is  necessary  to  develop
new  molecules  which  help  counteract  or  prevent  them.  The
discovery  and  development  of  new  drugs  begins  with  the
demonstration  of  the  pharmacological  effects,  to  later  con-
duct  safety  and  efﬁcacy  studies  in  human  beings.  In  vitro
models  are  widely  used;  they  are  fast,  cheap,  reproducible
techniques  and  require  a  lower  sample.  Nevertheless,  the
results  ought  to  be  reevaluated  by  other  models.  Ex  vivo
models  are  an  intermediate  point  between  in  vivo  and
in  vitro  models,  but  are  less  utilized.  Unlike  the  other  two,
in  vivo  models  provide  a  wide  range  of  information.  They
are  widely  used  to  verify  the  activity  of  new  compounds,
although  they  are  more  expensive  and  go  through  many
experimental  animals.  Hence,  they  are  generally  used  after
an  in  vitro  or  ex  vivo  evaluation,  as  a  step  previous  to  clinical
trials.
Conﬂict of interest
The  authors  have  no  conﬂicts  of  interest  to  declare.
Funding
No  ﬁnancial  support  was  provided.
Acknowledgements
Special  thanks  go  to  the  Mexican  National  Council  of  Science
and  Technology  (abbreviated  CONACYT)  for  their  support  for
the  national  scholarship  no.  359832  and  project  no.  180997
of  the  Basic  Scientiﬁc  Research  Grant  2012.
References
1. Groneberg DA, Grosse-Siestrup C, Fischer A. In vitro models to
study hepatotoxicity. Toxicol Pathol. 2002;30:394--9.
2. Vargas-Mendoza N, Madrigal-Santillán E, Morales-González A,
et al. Hepatoprotective effect of silymarin. World J Hepatol.
2014;6:144--9, http://dx.doi.org/10.4254/wjh.v6.i3.144.
3. Organización Mundial de la Salud. OMS-cirrosis; 2014
www.who.int/en
4. Waring WS. Novel acetylcysteine regimens for treatment
of paracetamol overdose. Ther Adv Drug Saf. 2012:305--15,
http://dx.doi.org/10.1177/2042098612464265.
5. Zhao XY, Zeng X, Li XM, et al. Pirfenidone inhibits carbon
tetrachloride- and albumin complex-induced liver ﬁbrosis in
rodents by preventing activation of hepatic stellate cells. Clin
Exp Pharmacol Physiol. 2009;36(10):963--8, http://dx.doi.org/
10.1111/j.1440-1681.2009.05194.x.
6. Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J,
et al. The multifaceted role of pirfenidone and its novel tar-
gets. Fibrogenes Tissue Repair. 2010;3:16, http://dx.doi.org/
10.1186/1755-1536-3-16.
7. Méndez-Sánchez N, Villa AR, Chavez-Tapia NC, et al. Trends in
liver disease prevalence in Mexico from 2005 to 2050 through
mortality data. Ann Hepatol. 2005;4:52--5.
8. Abdallah HM, Ezzat SM, El Dine RS, et al. Corrigendum
to ‘‘Protective effect of Echinops galalensis against CCl4-
induced injury on the human hepatoma cell line (Huh7)’’
2227
[Phytochem. Lett. 6 (2013) 73-78]. Phytochem Lett. 2013;6:471,
http://dx.doi.org/10.1016/j.phytol.2013.06.001.
9. Bhaargavi V, Jyotsna GSL, Tripurana R. A review on hepatopr-
tective activity. Int J Pharm Sci Res. 2007;5:690--702.
0. Fernando CD, Soysa P. Total phenolic, ﬂavonoid contents, in-
vitro antioxidant activities and hepatoprotective effect of
aqueous leaf extract of Atalantia ceylanica. BMC Complement
Altern Med. 2014:1--8.
1. Qureshi NN, Kuchekar BS, Logade NA, et al. Antioxidant
and hepatoprotective activity of Cordia macleodii leaves.
Saudi Pharm J: Off Publ Saudi Pharm Soc. 2009;17:299--302,
http://dx.doi.org/10.1016/j.jsps.2009.10.007.
2. Hiraganahalli BD, Chinampudur VC, Dethe S, et al. Hepatopro-
tective and antioxidant activity of standardized herbal extracts.
Pharmacogn Mag. 2012;8:116--23.
3. Tanikawa K, Torimura T. Studies on oxidative stress in
liver diseases: important future trends in liver research.
Med Mol Morphol. 2006;39:22--7, http://dx.doi.org/10.1007/
s00795-006-0313-z.
4. De la Morena GS, Martínez Pérez J. Efecto hepatoprotector
inducido por el ﬂavonoide Astilbina frente a un modelo ani-
mal  tratado con tetracloruro de carbono. Rev Cuba Plant Med.
1999;1:36--9.
5. Ai G, Liu Q, Hua W,  et al. Hepatoprotective evaluation of
the total ﬂavonoids extracted from ﬂowers of Abelmoschus
manihot (L.) Medic: in vitro and in vivo studies. J Ethnophar-
macol. 2013;146:794--802, http://dx.doi.org/10.1016/j.jep.
2013.02.005.
6. Ahmad F, Tabassum N. Experimental models used for the
study of antihepatotoxic agents. J Acute Dis. 2012;1:85--9,
http://dx.doi.org/10.1016/S2221-6189(13)60021-9.
7. Kumar E, Susmitha K, Swathy B, et al. A review on liver disorders
and screening models of hepatoprotective agents. Int J Allied
Med Sci Clin Res. 2014;2:136--50.
8. Kashaw V, Nema A, Agarwal A. Hepatoprotective prospective of
herbal drugs and their vesicular carriers -- a review. Int J Res
Pharm Biomed Sci. 2011;2:360--74.
9. Patil BR, Bamane SH, Khadsare UR. In vitro protection of hepa-
tocytes by Alocasia macrorrhiza leaf juice against CCl4 and
tylenol mediated hepatic injury. Int J Pharm Appl. 2011;2:
122--7.
0. Vodovotz Y, Kim P, Bagci E, et al. Inﬂammatory modula-
tion of hepatocyte apoptosis by nitric oxide: in vivo, in
vitro, and in silico studies. Curr Mol Med. 2004;4:753--62,
http://dx.doi.org/10.2174/1566524043359944.
1. Olinga P, Schuppan D. Precision-cut liver slices: a tool
to model the liver ex vivo. J Hepatol. 2013;58:1252--3,
http://dx.doi.org/10.1016/j.jhep.2013.01.009.
2. Gandolﬁ JA, Wijeweera J, Brendel K. Use of precision-cut
liver slices as an in vitro tool for evaluating liver func-
tion. Toxicol Pathol. 1996;24(1):58--61, http://dx.doi.org/
10.1177/019262339602400108.
3. Guillouzo A. Liver cell models in in vitro toxicology. Environ
Health Perspect. 1998;106.
4. Van de Bovenkamp M, Groothuis GMM, Meijer DKF,
et al. Liver ﬁbrosis in vitro: cell culture models and
precision-cut liver slices. Toxicol In Vitro. 2007;21:545--57,
http://dx.doi.org/10.1016/j.tiv.2006.12.009.
5. Ebadollahi Natanzi A, Ghahremani MH, Minaei B, et al. An exper-
imental model for study of the hepatoprotective activity of
Nasturtium ofﬁcinale (Watercress) against acetaminofen toxic-
ity using in situ rat liver system. Eur J Sci Res. 2009;38:556--64.
6. Roth RA, Ganey PE. Intrinsic versus idiosyncratic drug-
induced hepatotoxicity -- two villains or one? J Pharma-
col Exp Ther. 2010;332(3):692--7, http://dx.doi.org/10.1124/
jpet.109.162651.wisdom.
7. Russmann S, Kullak-Ublick G, Grattagliano I. Current con-
cepts of mechanisms in drug-induced hepatotoxicity. Curr
22
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
428  
Med Chem. 2009;16(23):3041--53, http://dx.doi.org/10.2174/
092986709788803097.
8. Rajesh A, Vijay K, Pravesh KS, et al. Hepatoprotective models
and screening methods: a review. J Discov Ther. 2014;2:49--56.
9. Robin S, Sunil K, Rana AC, et al. Different models of hepato-
toxicity abs related liver diseases: a review. Int Res J Pharm.
2012;3:86--95.
0. Vasanth PR, Raghu HC, Vijayan P, et al. In vitro and in vivo
hepatoprotective effects of the total alkaloid fraction of
Hygrophila auriculata leaves. Indian J Pharmacol. 2010;42:
99--104.
1. Zhou G, Chen Y, Liu S, et al. In vitro and in vivo hepato-
protective and antioxidant activity of ethanolic extract
from Meconopsis integrifolia (Maxim.) Franch. J Ethnophar-
macol. 2013;148:664--70, http://dx.doi.org/10.1016/j.jep.
2013.05.027.
2. Shailajan S, Joshi M, Tiwari B. Hepatoprotective activity of
Parmelia perlata (Huds.) Ach. against CCl4 induced liver tox-
icity in Albino Wistar rats. J Appl Pharm Sci. 2014;4:70--4,
http://dx.doi.org/10.7324/JAPS.2014.40212.
3. Wang A-Y. Gentiana manshurica Kitagawa prevents
acetaminophen-induced acute hepatic injury in mice via
inhibiting JNK/ERK MAPK pathway. World J Gastroenterol.
2010;16:384, http://dx.doi.org/10.3748/wjg.v16.i3.384.
4. McGill MR, Sharpe MR, Williams CD, et al. The mecha-
nism underlying acetaminophen-induced hepatotoxicity
in humans and mice involves mitochondrial damage and
nuclear DNA fragmentation. J Clin Invest. 2012;122:1574--83,
http://dx.doi.org/10.1172/JCI59755.
5. Jaeschke H, Gores GJ, Cederbaum AI, et al. Mechanisms of
hepatotoxicity. Toxicol Sci. 2002;176:166--76.6. Simeonova R, Kondeva-Burdina M, Vitcheva V, et al. Some in
vitro/in vivo chemically-induced experimental models of liver
oxidative stress in rats. Biomed Res Int. 2014;2014:706302,
http://dx.doi.org/10.1155/2014/706302.C.  Delgado-Montemayor  et  al.
7. Lim HK, Kim HS, Choi HS, et al. Effects of acetylbergenin against
d-galactosamine-induced hepatotoxicity in rats. Pharmacol Res.
2000;42:471--4, http://dx.doi.org/10.1006/phrs.2000.0730.
8. Raj PV, Nitesh K, Prateek J, et al. Effect of lecithin
on d-galactosamine induced hepatotoxicity through mito-
chondrial pathway involving Bcl-2 and Bax. Indian J Clin
Biochem. 2011;26:378--84, http://dx.doi.org/10.1007/s12291-
011-0155-x.
9. Wang C, Wang J, Lin W,  et al. Protective effect of hibiscus
anthocyanins against tert-butyl hydroperoxide-induced hepatic
toxicity in rats. Food Chem Toxicol. 2000;38:411--6.
0. Hwang J-M, Wang C-J, Chou F-P, et al. Protective effect
of baicalin on tert-butyl hydroperoxide-induced rat hepa-
totoxicity. Arch Toxicol. 2005;79:102--9, http://dx.doi.org/
10.1007/s00204-004-0588-6.
1. Akhtar T, Sheikh N. An overview of thioacetamide-induced hep-
atotoxicity. Toxin Rev. 2013;32:43--6.
2. Low TY, Leow CK, Salto-Tellez M, et al. A proteomic analysis of
thioacetamide-induced hepatotoxicity and cirrhosis in rat liv-
ers. Proteomics. 2004;4:3960--74, http://dx.doi.org/10.1002/
pmic.200400852.
3. Moustafa AHA, Ali EMM, Moselhey SS, et al. Effect of
coriander on thioacetamide-induced hepatotoxicity in rats.
Toxicol Ind Health. 2012;30:621--9, http://dx.doi.org/10.1177/
0748233712462470.
4. Henry JB, Ernard. Laboratorio, vol. 20. Marbán; 2007.
5. Donfack JH, Fotso GW, Ngameni B, et al. In vitro hepatopro-
tective and antioxidant activities of the crude extract and
isolated compounds from Irvingia gabonensis.  Asian J Tradit
Med. 2010;5:79--88.
6. Kikkawa R, Yamamoto T, Fukushima T, et al. Investigation of
a hepatotoxicity screening system in primary cell cultures --
‘‘what biomarkers would need to be addressed to estimate
toxicity in conventional and new approaches?’’. J Toxicol Sci.
2005;30:61--72, http://dx.doi.org/10.2131/jts.30.61.
